The University of California, Los Angeles (UCLA) received a $374,000 Project Grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). Through this award, UCLA aims to develop and optimize an Amyloid Beta (Aβ)-targeting chimeric antigen receptor (CAR) macrophage (CAR-M) therapy for Alzheimer's disease. The R61 phase of the project will focus on in vitro efficacy testing against Aβ aggregates and assessing the safety and central nervous system trafficking of the HSC-based CAR-M cells in vivo. The subsequent R33 phase will evaluate the short- and long-term efficacy of this therapy in Alzheimer's disease mouse models, measuring its impact on amyloid plaques, neuroinflammation, and behavioral outcomes. This innovative approach leverages expertise in CAR therapy and Alzheimer's disease research to potentially transform the treatment of this debilitating condition. The award was made on December 15, 2024 and has a targeted completion date of November 30, 2026.
Generated 2/25/25, 3:52 AM